NCT05217693 - A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

DRUG

BB-1705

BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.

Trial Locations (7)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

First affiliated hospital of Gannan medical university, Ganzhou

RECRUITING

Bliss Biopharmaceutical Co, Ltd, Hangzhou

RECRUITING

Zhejiang University School of Medicine - The First Affiliated Hospital, Hanzhou

RECRUITING

Linyi Cancer Hospital, Linyi

RECRUITING

Jiangsu Province Hospital, Nanjing

All Listed Sponsors

lead

Bliss Biopharmaceutical (Hangzhou) Co., Ltd

INDUSTRY